Preoperative Radiotherapy and Systemic Therapy Following Surgery in 'de Novo' Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- N/A
Clinical Trials Related to Metastatic Breast Cancer
Related studies linked through entity extraction aliases.
A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
- Status
- UNKNOWN
- Phase
- PHASE2
Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor.
- Status
- COMPLETED
- Phase
- NA
Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- N/A
Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy
- Status
- NOT_YET_RECRUITING
- Phase
- NA
A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)
- Status
- COMPLETED
- Phase
- PHASE3
Atezolizumab Plus CArboplatin Plus Nab-paclitaxel
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC
- Status
- WITHDRAWN
- Phase
- PHASE2
Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status
- Status
- COMPLETED
- Phase
- N/A
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
- Status
- TERMINATED
- Phase
- PHASE3
Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Roll-over Study to Allow Continued Access to Ribociclib
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE4
Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors
- Status
- COMPLETED
- Phase
- N/A
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m
- Status
- COMPLETED
- Phase
- N/A